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Inquilinus limosus is a new multiresistant pathogen isolated from the sputa of cystic
ﬁbrosis (CF) patients. Because this bacterium is not recorded in all commercial
identiﬁcation system databases currently available, Longitudinal study for I. limosus
detection with a new real-time PCR assay with a Taqman* probe targeting the 16S
rRNA gene was developed. From January 2006 to June 2007, 436 sputum samples
recovered from 145 CF patients and 54 non-CF patients were screened blindly for
the presence of I. limosus. Using our real-time PCR, we have detected 9 I. limosus
positive PCR in sputa from four CF patients (2.8%) that were also culture positive
in 8 cases. Interestingly, in one patient, I. limosus was detected using real-time
PCR three months before the culture was positive. Speciﬁcity of our real-time PCR
was veriﬁed using the programme BLAST and also using suspension of several
pathogens recovered habitually in CF patients. For the sensitivity: the minimal
numbers of CFU detectable was 2 CFU/PCR.
In conclusion I. limosus should be added in the list of emerging multiresistant
pathogens retrieved in CF patients. Thus, we have developed a real-time PCR as
a molecular method faster and easier than the ampliﬁcation-sequencing for prompt
detection of I. limosus with very good speciﬁcity and sensitivity.
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Introduction: Nocardia spp. are seldom reported as pathogens for respiratory
infection in CF. Signiﬁcance and interpretation of such isolations have to be
considered.
Case: We describe a 16 years old female with stable CF, colonized with S. aureus
(MSSA) since more than 10 years. Nutritional status is normal with BMI = P50, and
lung disease is moderate with stable lungfunction, FVC being 82% and FEV1= 85%
of predicted values. Recently, she presented with a moderate exacerbation of cough
and increased sputum production, without fever and deterioration of lung function.
Chest X-ray was stable. Nocardia farcinica was cultured together with S. aureus.
Treatment with anti-staph antibiotics (amoxyclav) was effective. However, Nocardia
farcinica was cultured again in 2 control sputum samples in a period of 3 weeks.
Although there were no acute respiratory symptoms, the patient was commenced
on cotrimoxazole (160mg/800mg, b.i.d.) for a period of 3 months.
Discussion: Nocardia spp. are aerobic Gram-positive bacteria, infecting mostly the
respiratory tract of subjects with immunosuppression or with underlying pulmonary
disease. Corticosteroids are important cofactors for infection. Nocardiosis is rarely
described in CF, and this patient did not receive any steroids. Details for treatment
indication in CF are not given. Motivation for treatment in CF is concern for
possible dissemination and deterioration.
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Between January 2005 and June 2007 8 patients, from a total adult and paediatric
population of approximately 500, were identiﬁed to regularly have a sputum culture
positive for Geosmithia argillacea (GA). This fungus is known to be closely related
to Penicillium species and was identiﬁed by ITS1 and LSU rRNA DNA sequence.
Examination of archived fungal strains revealed that this organism was isolated
from a CF patient (at a different institution) in 1991. GA has occasionally been
isolated from respiratory specimens in other non-CF patients and from specimens
suggesting possible involvement in deep-seated infections. Although GA is not
recognised to be a pathogen in the CF lung its ability to grow at temperatures of
up to 45ºC and its persistence in sputum cultures suggest it could be important
particularly following lung transplantation.
Patients colonised with GA had a median age of 20 years (6−27), FEV1 of 56%
(15−82) and duration of colonisation of up to 29 months. Over the same time period
all affected patients had sputum specimens positive for Aspergillus fumigatus, 5 of 8
also had positive samples for Pseudomonas aeruginosa andMycobacterium species,
2 of 8 had specimens positive for Burkholderia cepacia species and Staphylococcus
aureus.
In the opinion of the clinicians caring for the patients who had GA in sputum
specimens its appearance and persistence was not associated with a noticeable
change in their clinical condition. However, a concern remains that should these
patients become immunocompromised then GA may cause invasive disease.
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Objective: To analyze the gut microbiota composition of cystic ﬁbrosis (CF)
patients by classical culture and also molecular approaches.
Methods: Faecal samples from 18 CF patients and from 20 healthy volunteers
(HV) were seeded in selective media for bacterial isolating. Total DNA was obtained
from the faeces and quantitative-PCR experiments were conducted in order to know
the bacterial density for the Bacteroides, Fusobacterium, and Lactic Acid Bacteria
(LAB) groups. PCR-DGGE was performed with universal primers sets and also
with the described bacterial groups.
Results: Lower bacterial charge was found in the CF faecal samples than in the HV.
Curiously, Gram-negative bacteria were not detected in CF samples. Enterococcal
and staphylococcal clones were detected only in 10 and 9 CF patients, respectively,
whereas for HV these genera were represented in all subjects. Several LAB genera
as Lactococcus, Lactobacillus, and Pediococcus were detected in almost 50% of
the CF samples. Quantitative-PCR results showed differences among the density
proportions of the bacterial groups in the CF patients versus the HV: Bacteroides
(6:1), Fusobacterium (1.8:1), and LAB (2:1) groups. DGGE-experiments showed
particular bands associated only to CF patients.
Conclusion: Signiﬁcant differences were detected in the CF gut microbiota compo-
sition comparing with HV, being relevant the higher amounts of anaerobes and the
absence of Gram-negative cultivable organism. These differences can be related
with antimicrobial selective pressure and particular gut mucosal conditions in
CF patients.
